Stiefel Laboratories Buys Out Connetics for $640 Million
Filed in archive Corporate and Industrial News on October 24, 2006
Stiefel Laboratories Inc., a pharmaceutical firm specializing in dermatology, has bought one of Silicon Valley's biggest biotechnology companies, Connetics, for $17.50 a share --a 49 percent premium over the stock's price of $11.71 at the stock market's close Friday-- for an aggregate value of approximately $640 million.
"The combination of Stiefel and Connetics will create the world's premier dermatology company with a strong global presence in both branded and generic markets, dozens of marketed products and the most robust development pipeline in the industry. After the combination, Stiefel Laboratories, Inc. will have more than 3,500 employees worldwide, with more than 30 subsidiaries and sales in more than 100 countries."
Among the latest product in Connetics pipeline approved by the FDA is Verdeso(TM) (desonide) Foam, 0.05%, for the treatment of mild-to-moderate atopic dermatitis.
See more details of the merger from The Mercury News, and from Stiefel's and Connetics' press releases.

Tags: dermatology merger pharmaceutical biotech connetics stiefel+laboratories connetics+million buys+conn
Vote for Stiefel Laboratories Buys Out Connetics for $640 Million:
|
Rating: 9.75 out of 4 vote(s) cast.
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
